RecruitingNot ApplicableNCT07523477
Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis
Evaluation of Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis
Sponsor
Tanta University
Enrollment
64 participants
Start Date
Jun 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study is to evaluate the outcome of botulinum toxin A (BTX-A) injection for management of children with : A-Dysfunctional voiding who are not responding to traditional treatment. B-Refractory nocturnal enuresis.
Eligibility
Max Age: 18 Years
Inclusion Criteria3
- Children < 18 years.
- Both sexes.
- Patients with refractory nocturnal enuresis or dysfunctional voiding who are not responding to the traditional treatment.
Exclusion Criteria4
- Bleeding disorders.
- Neuromusclar disorder(e.g.,Myasthenia gravis).
- Patients who are not fit for anaesthesia.
- Active urinary tract infection (UTI).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGBotulinium Toxin-A
Patients will be injected with botulinium toxin-A
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07523477
Related Trials
Effects of Cartoons and Mobile Games on Preoperative Anxiety and Fear in Children With Appendicitis: An RCT
NCT076402301 location
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
NCT05457283179 locations
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
NCT070438941 location
Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
NCT069267511 location
A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults
NCT067614171 location